Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose hydrocortisone for severe community-acquired pneumonia (ICU)
2015-001239-19Phase 3Terminated
- Sponsor
- CHRU Tours
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in community-acquired pneumonia (CAP) comparing Hydrocortisone with Placebo (2 arms). Primary endpoint: D28 all-cause mortality. Started Jul 2015; status: terminated.
02
Drugs
hydrocortisone
03
Conditions
community-acquired pneumonia (CAP)
Beyond the preview
Go deeper on 2015-001239-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001239-19.